Koji Miura Net Worth

Koji Miura biography

Koji Miura serves as Independent Director of the Company. Mr. Miura has served as a director since October 2012. Mr. Miura is the founder and Managing Director of Miura & Associates Management Consultants Pte. Ltd. and serves on the boards of directors of Azeus Systems Holdings Ltd., Marine Tec Tachibana Pte. Ltd., Matsuura Singapore Pte. Ltd., Mercury Investment Holding Pte. Ltd., Sunmoon Pte. Ltd., and Triple Farm Singapore Pte. Ltd. Mr. Miura holds a bachelor’s degree in Business Administration from the University of Aoyama Gakuin, Tokyo, Japan.

What is the salary of Koji Miura?

As the Independent Director of Wave Life Sciences, the total compensation of Koji Miura at Wave Life Sciences is $150,876. There are 14 executives at Wave Life Sciences getting paid more, with Paul Bolno having the highest compensation of $3,581,530.

How old is Koji Miura?

Koji Miura is 71, he's been the Independent Director of Wave Life Sciences since 2012. There are no older and 18 younger executives at Wave Life Sciences.

What's Koji Miura's mailing address?

Koji's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.

Insiders trading at Wave Life Sciences

Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ..., and Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.

What does Wave Life Sciences do?

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Wave Life Sciences executives and stock owners

Wave Life Sciences executives and other stock owners filed with the SEC include:

• Paul Bolno,
  President, Chief Executive Officer, Director
• Christopher Francis,
  Senior Vice President - Corporate Development, Head of Emerging Areas
• Michael Panzara,
  Chief Medical Officer
• Chandra Vargeese,
  Senior Vice President, Head of Drug Discovery
• Dr. Paul B. Bolno M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. Michael A. Panzara M.D., M.P.H., MPH,
  Chief Medical Officer and Head of Therapeutics Discovery & Devel.
• Dr. Chandra Vargeese Ph.D.,
  Chief Technology Officer
• Gregory Verdine,
  Director
• Mark Corrigan,
  Independent Director
• Amy Pott,
  Independent Director
• Heidi Wagner,
  Independent Director
• Christian Henry,
  Independent Chairman of the Board
• Peter Kolchinsky,
  Independent Director
• Ken Takanashi,
  Independent Director
• Adrian Rawcliffe,
  Independent Director
• Koji Miura,
  Independent Director
• Kenneth Rhodes,
  Senior Vice President - Therapeutics Discovery
• David Gaiero,
  Interim Chief Financial Officer
• Kate Rausch,
  Investor Relations
• Anne-Marie Li-Kwai-Cheung,
  Sr. VP of Regulatory Affairs, Compliance & Policy
• Dr. Sridhar Vaddeboina Ph.D.,
  Sr. VP of Chemistry, Manufacturing & Controls
• Jose Juves,
  Sr. VP of Corp. Affairs & Patient Advocacy
• Jonathan Rosin,
  Chief HR Officer
• Dr. Christopher Francis Ph.D.,
  Sr. VP of Corp. Devel. & Head of Emerging Areas
• Linda Rockett J.D.,
  Gen. Counsel
• Kyle B. Moran CFA,
  CFO & Principal Accounting Officer
• Chris Francis,
  See Remarks
• Plc Gsk,
  10% owner
• Keith Regnante,
  Chief Financial Officer
• Takeshi Wada,
  Director
• Ken Shin Nippon Biomedical ...,
  
• Masaharu Kagoshima Shinsang...,
  
• Roberto Guerciolini,
  See Remarks
• Masaharu Tanaka,
  Director
• Peter Kolchinsky,
  Director
• Capital Management, Llc Kol...,
  
• Mark Baldry,
  Chief Commerical Officer
• Capital Management, L.P.Ra ...,
  
• Kyle Moran,
  Chief Financial Officer
• Aik Na Tan,